The appropriate sample-handling procedure for measuring the plasma β-amyloid level using a fully automated immunoassay.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 06 2024
20 06 2024
Historique:
received:
22
02
2024
accepted:
18
06
2024
medline:
21
6
2024
pubmed:
21
6
2024
entrez:
20
6
2024
Statut:
epublish
Résumé
Plasma β-amyloid (Aβ) assays are a promising tool for Alzheimer's disease diagnosis in clinical practice. To obtain reliable results, establishing an appropriate sample-handling procedure for each analytical platform is warranted. This study proposes an appropriate sample-handling procedure using HISCL analyzer by elucidating the individual/combined effects of pre-analytical parameters on plasma Aβ42/Aβ40 levels. We investigated the effects of various pre-analytical parameters, including storage times for whole blood, plasma, and freezing conditions, on plasma Aβ42/Aβ40 levels, and confirmed if these values met the acceptable criteria. Plasma Aβ42/Aβ40 levels were acceptable in all conditions. We determined our protocol by confirming that plasma Aβ42/Aβ40 levels remained acceptable when combining pre-analytical parameters. We established an appropriate sample-handling protocol that ensures reliable measurement of plasma Aβ42/Aβ40 levels using HISCL analyzer. We believe the Aβ assay, with our protocol, shows promise for aiding AD diagnosis in clinical settings.
Identifiants
pubmed: 38902510
doi: 10.1038/s41598-024-65264-1
pii: 10.1038/s41598-024-65264-1
doi:
Substances chimiques
Amyloid beta-Peptides
0
Peptide Fragments
0
amyloid beta-protein (1-40)
0
amyloid beta-protein (1-42)
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14266Informations de copyright
© 2024. The Author(s).
Références
Gauthier, S., Webster, C., Servaes, S., Morais, J. A., & Rosa-Neto, P. World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. London, England: Alzheimer’s Disease International. https://www.alzint.org/u/World-Alzheimer-Report-2022.pdf . (2022).
World Health Organization. Global action plan on the public health response to dementia 2017–2025. https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025 . (2017).
Vaz, M. & Silvestre, S. Alzheimer’s disease: recent treatment strategies. Eur. J. Pharmacol. 887, 173554 (2020).
doi: 10.1016/j.ejphar.2020.173554
pubmed: 32941929
Iwatsubo, T. et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45–53 (1994).
doi: 10.1016/0896-6273(94)90458-8
pubmed: 8043280
Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 1275–1283 (2010).
doi: 10.1016/j.neurobiolaging.2010.04.007
pubmed: 20472326
Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992).
doi: 10.1126/science.1566067
pubmed: 1566067
Korczyn, A. D. The amyloid cascade hypothesis. Alzheimers Dement. 4, 176–178 (2008).
doi: 10.1016/j.jalz.2007.11.008
pubmed: 18631966
Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 311–321 (2014).
doi: 10.1056/NEJMoa1312889
pubmed: 24450890
Salloway, S., Sperling, R. & Brashear, H. R. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease. N. Engl. J. Med. 370, 1460 (2014).
doi: 10.1056/NEJMoa1304839
pubmed: 24724181
Espay, A. J. Donanemab in early Alzheimer’s disease. N. Engl. J. Med. 385, 666–667 (2021).
doi: 10.1056/NEJMc2109455
pubmed: 34379933
Bateman, R. J. et al. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease. Alzheimers Res. Ther. 14, 178 (2022).
doi: 10.1186/s13195-022-01110-8
pubmed: 36447240
pmcid: 9707418
Dunn, B., Stein, P. & Cavazzoni, P. Approval of aducanumab for Alzheimer disease-the FDA’s perspective. JAMA Intern. Med. 181, 1276–1278 (2021).
doi: 10.1001/jamainternmed.2021.4607
pubmed: 34254984
van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023).
doi: 10.1056/NEJMoa2212948
pubmed: 36449413
Cummings, J. et al. Aducanumab: appropriate use recommendations update. J. Prev. Alzheimers Dis. 9, 221–230 (2022).
pubmed: 35542993
pmcid: 9169517
Mead, S. & Fox, N. C. Lecanemab slows Alzheimer’s disease: hope and challenges. Lancet Neurol. 22, 106–108 (2023).
doi: 10.1016/S1474-4422(22)00529-4
pubmed: 36681438
Gunawardena, I. P. C., Retinasamy, T. & Shaikh, M. F. Is aducanumab for LMICs? Promises and challenges. Brain Sci. 11, 1547 (2021).
doi: 10.3390/brainsci11111547
pubmed: 34827546
pmcid: 8615623
Zetterberg, H. Blood-based biomarkers for Alzheimer’s disease-An update. J. Neurosci. Methods 319, 2–6 (2019).
doi: 10.1016/j.jneumeth.2018.10.025
pubmed: 30352211
Varesi, A. et al. Blood-based biomarkers for Alzheimer’s disease diagnosis and progression: an overview. Cells 11, 1367 (2022).
doi: 10.3390/cells11081367
pubmed: 35456047
pmcid: 9044750
Leuzy, A. et al. Blood-based biomarkers for Alzheimer’s disease. EMBO Mol. Med. 14, e14408 (2022).
doi: 10.15252/emmm.202114408
pubmed: 34859598
Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 21, 66–77 (2022).
doi: 10.1016/S1474-4422(21)00361-6
pubmed: 34838239
Nakamura, A. et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554, 249–254 (2018).
doi: 10.1038/nature25456
pubmed: 29420472
Rabe, C. et al. Clinical performance and robustness evaluation of plasma amyloid-β
doi: 10.1002/alz.12801
pubmed: 36150024
Brand, A. L. et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review. Alzheimers Res. Ther. 14, 195 (2022).
doi: 10.1186/s13195-022-01117-1
pubmed: 36575454
pmcid: 9793600
Schindler, S. E. et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 93, e1647–e1659 (2019).
doi: 10.1212/WNL.0000000000008081
pubmed: 31371569
pmcid: 6946467
Janelidze, S. et al. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer disease. JAMA Neurol. 78, 1375–1382 (2021).
doi: 10.1001/jamaneurol.2021.3180
pubmed: 34542571
Yamashita, K. et al. Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy. Alzheimers Res. Ther. 14, 86 (2022).
doi: 10.1186/s13195-022-01029-0
pubmed: 35739591
pmcid: 9219197
Rózga, M., Bittner, T., Batrla, R. & Karl, J. Preanalytical sample handling recommendations for Alzheimer’s disease plasma biomarkers. Alzheimers Dement. (Amst) 11, 291–300 (2019).
doi: 10.1016/j.dadm.2019.02.002
pubmed: 30984815
Ashton, N. J. et al. Effects of pre-analytical procedures on blood biomarkers for Alzheimer’s pathophysiology, glial activation, and neurodegeneration. Alzheimers Dement. (Amst) 13, e12168 (2021).
doi: 10.1002/dad2.12168
pubmed: 34124336
Verberk, I. M. W. et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: results from the standardization of Alzheimer’s blood biomarkers (SABB) working group. Alzheimers Dement. 18, 1484–1497 (2022).
doi: 10.1002/alz.12510
pubmed: 34845818
Kurz, C. et al. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer’s disease. J. Neurochem. 165, 95–105 (2023).
doi: 10.1111/jnc.15757
pubmed: 36625424
Musso, G. et al. Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer’s disease. Clin. Chem. Lab. Med. 61, e53–e56 (2022).
doi: 10.1515/cclm-2022-0770
pubmed: 36423341
Boedeker, W. & Backhaus, T. The scientific assessment of combined effects of risk factors: Different approaches in experimental biosciences and epidemiology. Eur. J. Epidemiol. 25, 539–546 (2010).
doi: 10.1007/s10654-010-9464-2
pubmed: 20495951
Boon, B. D. C. et al. The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease. Acta Neuropathol. 140, 811–830 (2020).
doi: 10.1007/s00401-020-02198-8
pubmed: 32926214
pmcid: 7666300
Binette, A. P. et al. Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 19, 1403–1414 (2023).
doi: 10.1002/alz.12787
Doecke, J. D. et al. Total Aβ
doi: 10.1212/WNL.0000000000009240
pubmed: 32179698
pmcid: 7251518
Yamashita, K. et al. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for β-amyloid (1–40) and (1–42) in plasma samples. Biochem. Biophys. Res. Commun. 576, 22–26 (2021).
doi: 10.1016/j.bbrc.2021.08.066
pubmed: 34478915